Skandinaviska Enskilda Banken AB publ Lowers Stock Holdings in United Therapeutics Corporation $UTHR

Skandinaviska Enskilda Banken AB publ lessened its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 78.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 18,982 shares of the biotechnology company’s stock after selling 70,978 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in United Therapeutics were worth $7,951,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Norges Bank acquired a new stake in United Therapeutics in the 2nd quarter worth about $136,453,000. Invesco Ltd. boosted its position in shares of United Therapeutics by 90.2% in the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after acquiring an additional 419,588 shares during the last quarter. AQR Capital Management LLC grew its holdings in United Therapeutics by 40.1% in the second quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock valued at $362,876,000 after purchasing an additional 364,713 shares during the period. Assetmark Inc. increased its position in United Therapeutics by 38.1% during the second quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock worth $205,695,000 after purchasing an additional 197,384 shares during the last quarter. Finally, Balyasny Asset Management L.P. raised its stake in United Therapeutics by 863.9% during the second quarter. Balyasny Asset Management L.P. now owns 152,727 shares of the biotechnology company’s stock worth $43,886,000 after purchasing an additional 136,883 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $476.05 on Thursday. The business’s 50-day simple moving average is $485.84 and its 200 day simple moving average is $437.55. The company has a market cap of $20.50 billion, a P/E ratio of 18.04, a PEG ratio of 2.57 and a beta of 0.85. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $519.99.

Insider Activity

In related news, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction on Monday, February 9th. The shares were sold at an average price of $474.65, for a total transaction of $10,679,625.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Christopher Causey sold 1,000 shares of the business’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $510.00, for a total transaction of $510,000.00. Following the completion of the transaction, the director owned 4,190 shares in the company, valued at $2,136,900. This represents a 19.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 450,714 shares of company stock worth $218,011,238 over the last 90 days. Company insiders own 10.30% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Jefferies Financial Group restated a “buy” rating and set a $575.00 price objective on shares of United Therapeutics in a report on Wednesday, November 19th. UBS Group reissued a “buy” rating on shares of United Therapeutics in a research report on Tuesday. HC Wainwright raised their price objective on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Wells Fargo & Company boosted their target price on United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a report on Thursday, October 30th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research report on Monday, December 29th. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $509.50.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.